Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een onderzoek om de werkzaamheid en veiligheid van anifrolumab bij volwassenen met chronische en/of subacute cutane lupus erythematosus te onderzoeken (LAVENDER)

10 november 2026 bijgewerkt door: AstraZeneca

Een multicenter, gerandomiseerde, dubbelblinde, placebogecontroleerde fase III-studie om de werkzaamheid en veiligheid van anifrolumab te evalueren bij volwassenen met chronische en/of subacute cutane lupus erythematosus die refractair en/of intolerant zijn voor antimalariatherapie

This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).

Studie Overzicht

Toestand

Actief, niet wervend

Gedetailleerde beschrijving

This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

339

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Ciudad de Buenos Aires, Argentinië, 1221
        • Research Site
      • Córdoba, Argentinië, 5000
        • Research Site
      • Córdoba, Argentinië, X5004BAL
        • Research Site
      • Quilmes, Argentinië, 1878
        • Research Site
      • San Miguel, Argentinië, 1663
        • Research Site
      • Kogarah, Australië, 3168
        • Research Site
      • Melbourne, Australië, 3004
        • Research Site
      • Mitcham, Australië, 3132
        • Research Site
      • Westmead, Australië, 2145
        • Research Site
      • Woolloongabba, Australië, 04102
        • Research Site
      • Belo Horizonte, Brazilië, 30150-221
        • Research Site
      • Porto Alegre, Brazilië, 90035903
        • Research Site
      • Rio de Janeiro, Brazilië, 22470-220
        • Research Site
      • Salvador, Brazilië, 40150-150
        • Research Site
      • São Paulo, Brazilië, 05403-000
        • Research Site
      • Sofia, Bulgarije, 1784
        • Research Site
      • Sofia, Bulgarije, 1463
        • Research Site
      • Sofia, Bulgarije, 1528
        • Research Site
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 1M9
        • Research Site
    • Ontario
      • Hamilton, Ontario, Canada, L8N 3Z5
        • Research Site
      • Toronto, Ontario, Canada, M5T 2S8
        • Research Site
      • Osorno, Chili, 200025
        • Research Site
      • Santiago, Chili, 7500571
        • Research Site
      • Santiago, Chili, 130021
        • Research Site
      • Changchun, China, 130021
        • Research Site
      • Changsha, China, 410011
        • Research Site
      • Chengdu, China, 610021
        • Research Site
      • Chongqing, China, 400016
        • Research Site
      • Dongguan, China, 523059
        • Research Site
      • Guangzhou, China, 510120
        • Research Site
      • Heilongjiang, China, 150086
        • Research Site
      • Jinan, China, 250022
        • Research Site
      • Shanghai, China, 200025
        • Research Site
      • Shanghai, China, 200443
        • Research Site
      • Shenzhen, China, 518053
        • Research Site
      • Shenzhen, China, 518020
        • Research Site
      • Shenzhen, China, 518052
        • Research Site
      • Zhuzhou, China, 412007
        • Research Site
      • Ürümqi, China, CN-830004
        • Research Site
      • Barranquilla, Colombia, 080020
        • Research Site
      • Bogotá, Colombia, 110221
        • Research Site
      • Aarhus, Denemarken, 641-8510
        • Research Site
      • Copenhagen, Denemarken, 2100
        • Research Site
      • Berlin, Duitsland, 10117
        • Research Site
      • Bochum, Duitsland, 44791
        • Research Site
      • Dresden, Duitsland, 01307
        • Research Site
      • Erlangen, Duitsland, 91054
        • Research Site
      • Essen, Duitsland, 45147
        • Research Site
      • Freiburg im Breisgau, Duitsland, 79104
        • Research Site
      • Hanover, Duitsland, 30625
        • Research Site
      • Kiel, Duitsland, 24105
        • Research Site
      • Leipzig, Duitsland, 04103
        • Research Site
      • Mainz, Duitsland, 55131
        • Research Site
      • Marburg, Duitsland, 35043
        • Research Site
      • Regensburg, Duitsland, 93053
        • Research Site
      • Wuppertal, Duitsland, 42283
        • Research Site
      • Iloilo City, Filippijnen, 5000
        • Research Site
      • Lipa, Filippijnen, 4217
        • Research Site
      • Manila, Filippijnen, 1000
        • Research Site
      • Bois-Guillaume, Frankrijk, 76031
        • Research Site
      • Dijon, Frankrijk, 21000
        • Research Site
      • Lyon, Frankrijk, 69437
        • Research Site
      • Montivilliers, Frankrijk, 76290
        • Research Site
      • Nantes, Frankrijk, 44000
        • Research Site
      • Paris, Frankrijk, 75010
        • Research Site
      • Paris, Frankrijk, 75014
        • Research Site
      • Paris, Frankrijk, 75013
        • Research Site
      • Paris, Frankrijk, 75970
        • Research Site
      • Poitiers, Frankrijk, 86000, FR
        • Research Site
      • Toulouse, Frankrijk, 31059
        • Research Site
      • Athens, Griekenland, 12462
        • Research Site
      • Athens, Griekenland, 16121
        • Research Site
      • Brescia, Italië, 25123
        • Research Site
      • Cona, Italië, 44124
        • Research Site
      • Florence, Italië, 50121
        • Research Site
      • Milan, Italië, 20132
        • Research Site
      • Naples, Italië, 80138
        • Research Site
      • Reggio Emilia, Italië, 42123
        • Research Site
      • Roma, Italië, 00144
        • Research Site
      • Rome, Italië, 00168
        • Research Site
      • Chūōku, Japan, 104-8560
        • Research Site
      • Fukuoka, Japan, 812-8582
        • Research Site
      • Kanazawa, Japan, 920-8641
        • Research Site
      • Kita-gun, Japan, 761-0793
        • Research Site
      • Nagoya, Japan, 457-8510
        • Research Site
      • Nagoya, Japan, 467-8602
        • Research Site
      • Wakayama, Japan, 641-8510
        • Research Site
      • Yokohama, Japan, 232-0024
        • Research Site
      • tabashi City, Japan, 173-8606
        • Research Site
      • Guadalajara, Mexico, 44340
        • Research Site
      • Guadalajara, Mexico, 44610
        • Research Site
      • Mexico City, Mexico, 07760
        • Research Site
      • Veracruz, Mexico, 91910
        • Research Site
      • Breda, Nederland, 4818 CK
        • Research Site
      • Rotterdam, Nederland, 3015 GD
        • Research Site
      • Papatoetoe, Nieuw-Zeeland, 2025
        • Research Site
      • Graz, Oostenrijk, 8036
        • Research Site
      • Innsbruck, Oostenrijk, 6020
        • Research Site
      • Linz, Oostenrijk, 4020
        • Research Site
      • Vienna, Oostenrijk, 1130
        • Research Site
      • Katowice, Polen, 40-851
        • Research Site
      • Kielce, Polen, 25-316
        • Research Site
      • Ossy, Polen, 40-027
        • Research Site
      • Rzeszów, Polen, 35-055
        • Research Site
      • Warsaw, Polen, 02-637
        • Research Site
      • Braga, Portugal, 4710-243
        • Research Site
      • Lisbon, Portugal, 1649-035
        • Research Site
      • Porto, Portugal, 4099-001
        • Research Site
      • Bucharest, Roemenië, 020125
        • Research Site
      • Iași, Roemenië, 700291
        • Research Site
      • Belgrade, Servië, 11000
        • Research Site
      • Kragujevac, Servië, 34000
        • Research Site
      • Košice, Slowakije, 04001
        • Research Site
      • Piešťany, Slowakije, 92101
        • Research Site
      • Barcelona, Spanje, 8035
        • Research Site
      • Barcelona, Spanje, 08025
        • Research Site
      • Castellon, Spanje, 12004
        • Research Site
      • Granada, Spanje, 18012
        • Research Site
      • L'Hospitalet de Llobregat, Spanje, 08907
        • Research Site
      • Las Palmas de Gran Canaria, Spanje, 35010
        • Research Site
      • Madrid, Spanje, 28034
        • Research Site
      • Madrid, Spanje, 28041
        • Research Site
      • Madrid, Spanje, 28040
        • Research Site
      • Madrid, Spanje, 28006
        • Research Site
      • Majadahonda, Spanje, 28222
        • Research Site
      • Salamanca, Spanje, 37007
        • Research Site
      • Seville, Spanje, 41014
        • Research Site
      • Valencia, Spanje, 46014
        • Research Site
      • Valencia, Spanje, 46017
        • Research Site
      • Vigo, Spanje, 36200
        • Research Site
      • Kaohsiung City, Taiwan, 83301
        • Research Site
      • Taichung, Taiwan, 404
        • Research Site
      • Taipei, Taiwan, 10449
        • Research Site
      • Bangkok, Thailand, 10330
        • Research Site
      • Bangkok, Thailand, 10700
        • Research Site
      • Hat Yai, Thailand, 90110
        • Research Site
      • Khlong Luang, Thailand, 12120
        • Research Site
      • Khon Kaen, Thailand, 40002
        • Research Site
      • Cordaleo, Turkije (Türkiye), 35575
        • Research Site
      • Istanbul, Turkije (Türkiye), 34098
        • Research Site
      • Kayseri, Turkije (Türkiye), 38039
        • Research Site
      • Samsun, Turkije (Türkiye), 55270
        • Research Site
      • Cambridge, Verenigd Koninkrijk, CB2 0QQ
        • Research Site
      • Leeds, Verenigd Koninkrijk, LS2 9JT
        • Research Site
      • London, Verenigd Koninkrijk, NW1 2PG
        • Research Site
      • London, Verenigd Koninkrijk, SE5 9RS
        • Research Site
      • London, Verenigd Koninkrijk, SE1 7EH
        • Research Site
      • London, Verenigd Koninkrijk, NW3 2QG
        • Research Site
      • Newcastle upon Tyne, Verenigd Koninkrijk, NE1 4LP
        • Research Site
    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85028
        • Research Site
    • California
      • Covina, California, Verenigde Staten, 91722
        • Research Site
      • La Jolla, California, Verenigde Staten, 92037
        • Research Site
      • Los Angeles, California, Verenigde Staten, 90045
        • Research Site
      • Los Angeles, California, Verenigde Staten, 90089
        • Research Site
      • Orange, California, Verenigde Staten, 92868
        • Research Site
      • San Francisco, California, Verenigde Staten, 94143
        • Research Site
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
        • Research Site
    • Connecticut
      • New Haven, Connecticut, Verenigde Staten, 06519
        • Research Site
    • District of Columbia
      • Washington D.C., District of Columbia, Verenigde Staten, 20037
        • Research Site
    • Florida
      • Fort Lauderdale, Florida, Verenigde Staten, 33309
        • Research Site
      • Miami, Florida, Verenigde Staten, 33174
        • Research Site
      • Plantation, Florida, Verenigde Staten, 33324
        • Research Site
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60637
        • Research Site
      • Chicago, Illinois, Verenigde Staten, 60611
        • Research Site
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46202
        • Research Site
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21287
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Research Site
      • Boston, Massachusetts, Verenigde Staten, 02115-5817
        • Research Site
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48109
        • Research Site
      • Bloomfield Hills, Michigan, Verenigde Staten, 48302
        • Research Site
    • Minnesota
      • Rochester, Minnesota, Verenigde Staten, 55905
        • Research Site
    • Nebraska
      • Omaha, Nebraska, Verenigde Staten, 68198-5885
        • Research Site
    • New York
      • New York, New York, Verenigde Staten, 10028
        • Research Site
      • Rochester, New York, Verenigde Staten, 14642
        • Research Site
    • North Carolina
      • Charlotte, North Carolina, Verenigde Staten, 28207
        • Research Site
      • Statesville, North Carolina, Verenigde Staten, 28625
        • Research Site
    • Ohio
      • Cleveland, Ohio, Verenigde Staten, 44195
        • Research Site
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97239
        • Research Site
    • Rhode Island
      • Providence, Rhode Island, Verenigde Staten, 02903
        • Research Site
    • South Carolina
      • Charleston, South Carolina, Verenigde Staten, 29425
        • Research Site
    • Texas
      • Dallas, Texas, Verenigde Staten, 75390-8843
        • Research Site
    • Virginia
      • Charlottesville, Virginia, Verenigde Staten, 22903
        • Research Site
      • Roanoke, Virginia, Verenigde Staten, 24016
        • Research Site
      • Seoul, Zuid -Korea, 03080
        • Research Site
      • Seoul, Zuid -Korea, 06591
        • Research Site
      • Seoul, Zuid -Korea, 06973
        • Research Site
      • Cape Town, Zuid-Afrika, 7500
        • Research Site
      • Johannesburg, Zuid-Afrika, 2193
        • Research Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 70 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Key inclusion criteria:

  • Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following:

    • CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
    • Inadequate response or intolerant to antimalarial therapy.
  • Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.

  • Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Key exclusion criteria:

  • History or evidence of suicidal ideation.
  • Severe or life-threatening Systemic lupus erythematosus (SLE).
  • Active SLE or Sjögren's Syndrome.
  • Any active skin conditions other than CLE that may interfere with the study.
  • History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
  • History of recurrent infection requiring hospitalization and IV antibiotics.
  • COVID-19 infection.
  • Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
  • At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Anifrolumab

Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51.

Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).

Placebo-vergelijker: Placebo

Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51.

Matching placebo solution for injection in aPFS.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
Tijdsspanne: At Week 24

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder.

At Week 24

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from baseline in total CLASI-A score
Tijdsspanne: At Week 24

The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE.

At Week 24
Number of participants with CLASI-70 response
Tijdsspanne: At Week 12

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder.

At Week 12
Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score
Tijdsspanne: At Week 12

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients.

At Week 12
Number of participants with CLASI-50 response
Tijdsspanne: At Week 12 and Week 24

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder.

At Week 12 and Week 24
Number of participants who are sustained CLASI-70 responders
Tijdsspanne: Up to Week 52

The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated.

Up to Week 52
Serum trough (pre-dose) concentrations of anifrolumab
Tijdsspanne: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)

The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated.

Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
Number of participants with positive antidrug antibody
Tijdsspanne: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)

The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated.

Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
Percent change from baseline in suppression of the Interferon 21-gene
Tijdsspanne: Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)

The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated.

Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
Change from baseline in Skindex-29+3 Symptom domain scores
Tijdsspanne: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life.

At Week 24
Change from baseline in Skindex-29+3 Emotion domain scores
Tijdsspanne: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Change from baseline in Skindex-29+3 Function domain scores
Tijdsspanne: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Change from baseline in Skindex-29+3 Lupus-Specific domain scores
Tijdsspanne: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Change from baseline in Skindex-29+3 Total score
Tijdsspanne: At Week 24

The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE.

At Week 24
Time from IP start date to CLASI-70 response.
Tijdsspanne: From Week 0/Day 1 up to Week 24

To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE.

From Week 0/Day 1 up to Week 24
Time from IP start date to CLASI-50 response.
Tijdsspanne: From Week 0/Day 1 up to Week 24

To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE.

From Week 0/Day 1 up to Week 24

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of participants with adverse events
Tijdsspanne: Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)

To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE.

Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Medewerkers

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

29 juni 2024

Primaire voltooiing (Werkelijk)

2 november 2026

Studie voltooiing (Geschat)

10 augustus 2027

Studieregistratiedata

Eerst ingediend

1 augustus 2023

Eerst ingediend dat voldeed aan de QC-criteria

22 augustus 2023

Eerst geplaatst (Werkelijk)

29 augustus 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 november 2026

Laatste update ingediend die voldeed aan QC-criteria

10 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD-tijdsbestek voor delen

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-toegangscriteria voor delen

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren